<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314325</url>
  </required_header>
  <id_info>
    <org_study_id>2013-003240-23</org_study_id>
    <nct_id>NCT02314325</nct_id>
  </id_info>
  <brief_title>Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens</brief_title>
  <acronym>PERSONAL</acronym>
  <official_title>Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. James's Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter BioScience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to assess if there is evidence of subclinical joint bleeding on&#xD;
      MRI/X-Ray in adults with severe Haemophilia A while on standard and/or pharmacokinetically&#xD;
      tailored prophylaxis regimens. Participants with severe Haemophilia A will have longitudinal&#xD;
      MRI and XRay imaging of their elbows, ankles and knees at 0, 6 and 18 months while on&#xD;
      standard ( 0-6 months) and then pharmacokinetically tailored (7-18 months) recombinant Factor&#xD;
      VIII prophylaxis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subclinical joint bleeding (SJB) in Haemophilia may cause early and progressive joint damage.&#xD;
      Clinical haemarthrosis is a traditional outcome measure in Haemophilia trials but may not&#xD;
      always correlate with the degree of arthropathy. Even in the absence of haemarthrosis,&#xD;
      abnormalities may be detected on MRI. MRI offers greater sensitivity than physical&#xD;
      examination for early joint damage and use of the International Prophylaxis Study Group&#xD;
      (IPSG) score allows standardisation across clinical trials. Early awareness of haemophiliac&#xD;
      arthropathy can prompt intervention with physiotherapy, specific exercise programmes,&#xD;
      optimization of prophylaxis and orthotics to improve overall joint outcomes.&#xD;
&#xD;
      The time spent with Factor VIII (FVIII) levels &lt;0.01 IU/mL is a known risk for bleeding.&#xD;
      Conventional prophylaxis schedules follow a weight based regimen and are titrated according&#xD;
      to clinical bleeds. FVIII pharmacokinetics (PK) may be used to optimise FVIII prophylactic&#xD;
      regimens, maintaining adequate FVIII trough levels. This offers the possibility to not only&#xD;
      tailor individual regimens but also may potentially reduce the rate of clinical and&#xD;
      subclinical joint bleeding.&#xD;
&#xD;
      This is a national, investigator led clinical trial investigating the feasibility of PK&#xD;
      tailored prophylaxis in adults with severe Haemophilia A. This trial will prospectively and&#xD;
      longitudinally assess SJB and joint health in Irish adults with severe Haemophilia A.&#xD;
&#xD;
      SJB will be compared while on standard (weight based, 20-40 IU/kg) and PK tailored&#xD;
      prophylaxis(maintaining trough FVIII &gt; 0.015 IU/mL). This is a crossover study will&#xD;
      participants spending months 0-6 on standard prophylaxis and then changing over to PK&#xD;
      tailored dosing for months 7-18. A comprehensive joint assessment involving bleed history,&#xD;
      clinical examination, physical activity, specialist physiotherapy review, X-rays and MRI&#xD;
      scanning of bilateral ankles, knees and elbow will be performed at months 0,6 and 18.&#xD;
      Haemophilia Joint Health Score (HJHS), International Physical Activity (IPAQ) and EuroQoL&#xD;
      5-Dimensions (EQ5D) Questionnaires will also be performed at these three timepoints.&#xD;
&#xD;
      Clinical bleeds and FVIII usage will be recorded throughout the trial using the investigators&#xD;
      Home Scan system, a smart phone application that allows patients to log factor VIII usage.&#xD;
&#xD;
      Results will be compared between both arms and between participants on primary and secondary&#xD;
      prophylaxis. Information on those with na√Øve joints versus established arthropathy will be&#xD;
      compared.&#xD;
&#xD;
      Due to the relative rarity of severe Haemophilia A the investigators plan to recruit 20&#xD;
      patients in total. All patients will act as their own control, crossing over from standard to&#xD;
      PK tailored prophylaxis with joint assessments prior to crossover to allow comparison of the&#xD;
      two regimes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subclinical haemarthroses</measure>
    <time_frame>18 months</time_frame>
    <description>The number of subclinical haemarthroses identifed on serial MRI scans of elbow, knee and ankle joints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ5D QoL score</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of score on EQ5D Quality of life questionnaire on standard versus PK tailored dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of prescribed doses of prophylaxis taken</measure>
    <time_frame>18 months</time_frame>
    <description>The number of missed doses of prophylaxis on the standard and PK tailored dosing regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPAQ score</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of IPAQ activity scores (numeric) on standard versus PK tailored dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemophilia joint health score (HJHS)</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of HJHS numeric score on standard versus PK tailored dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of FVIII usage (units)</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of FVIII usage in units on standard versus PK tailored dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI joint score</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of joint score (numeric) determined on MRI by the International prophylaxis study group (IPSG) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Petterson joint score</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of Petterson joint score (numeric) on plain films for patients on standard versus PK tailored dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical haemarthroses</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patient reported haemarthroses on standard prophylaxis versus PK tailored prophylaxis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Standard prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetic tailored prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVATE [Antihemophilic Factor (Recombinant)]</intervention_name>
    <description>In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight</description>
    <arm_group_label>Standard prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVATE [Antihemophilic Factor (Recombinant)]</intervention_name>
    <description>In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen</description>
    <arm_group_label>Pharmacokinetic tailored prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients with severe Haemophilia A (baseline Factor VIII level of &lt;0.01 IU/mL)&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Patients taking any regular prophylactic regimen (defined as regular factor VIII&#xD;
             infusions, at least 5 times a fortnight, with the aim of minimising haemarthroses and&#xD;
             other clinically significant bleeds).&#xD;
&#xD;
          -  Low titre inhibitors, past history of an inhibitor, abnormal liver function, drugs&#xD;
             that interfere with haemostasis and low Cluster of Differentiation 4 (CD4) counts are&#xD;
             allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a target joint on prophylaxis (defined as 3 bleeds into one joint, during&#xD;
             a 6 month period, during the last year).&#xD;
&#xD;
          -  The occurrence of more than 3 haemarthroses in the last year that required more than 2&#xD;
             infusions to resolve.&#xD;
&#xD;
          -  Patients with a learning disability or dementia&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Adults who are unconscious/unable to give informed consent&#xD;
&#xD;
          -  Participants with a pacemaker or implanted medical devices which are unsuitable to&#xD;
             have a MRI will be excluded from the MRI scans during the trial but may proceed with&#xD;
             other components.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niamh M O'Connell, PhD, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. James's Hospital, Dublin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James O'Donnell, PhD, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. James's Hospital, Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle M Lavin, FRCPath</last_name>
    <phone>+35314162142</phone>
    <email>mlavin@stjames.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niamh M O'Connell, FRCPath</last_name>
    <phone>+35314162142</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niamh M O'Connell, FRCPath,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr. Niamh O'Connell</investigator_full_name>
    <investigator_title>Consultant Haematologist</investigator_title>
  </responsible_party>
  <keyword>Factor VIII deficiency</keyword>
  <keyword>Arthropathy</keyword>
  <keyword>MRI</keyword>
  <keyword>XRay</keyword>
  <keyword>Joint</keyword>
  <keyword>HJHS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

